You can now read 10 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe

Business

Mass. Movers

Biogen Idec jumps on Techfidera approval

Moody’s Investors Service also raised Biogen Idec’s ratings outlook to positive.

Suzanne Kreiter/Globe Staff/File

Moody’s Investors Service also raised Biogen Idec’s ratings outlook to positive.

Continue reading below

It was a good week for Biogen Idec Inc. shares after US regulators OK’d its first pill to treat multiple sclerosis, cementing the Weston company’s dominance in MS treatments. The FDA approved Tecfidera as a “first-line” treatment, meaning doctors can prescribe it for newly diagnosed patients and those already taking MS drugs. Analysts say Tecfidera potentially could become one of the top-selling prescription drugs of all time by the end of the decade.

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week